CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Clinical trial NCT06305910 · RECRUITING

Trial details

NCT number: NCT06305910
Sponsor: OX2 Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Midline Glioma, H3 K27M-Mutant Recurrent High Grade Glioma

Start date: 2024-03-15
Primary completion: 2025-09-15
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.